MedPath

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Phase 3
Recruiting
Conditions
Plaque Psoriasis
Registration Number
JPRN-jRCT2031230583
Lead Sponsor
Shikamura Mitsuhiro
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
600
Inclusion Criteria

1.Plaque psoriasis for at least 6 months.
2.Moderate to severe disease.
3.Candidate for phototherapy or systemic therapy.
Other protocol defined inclusion criteria apply.

Exclusion Criteria

1.Other forms of psoriasis.
2.History of recent infection.
3.Prior exposure to TAK-279 or active comparator.
Other protocol defined exclusion criteria apply.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath